Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nivolumab alone or nivolumab + ipilimumab versus investigator's choice chemotherapy in MSI-H/dMMR metastatic colorectal cancer
jRCT2080224841Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in colorectal cancer (CRC) (3 arms), sponsored by Ono Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080224841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224841.